To the Editor: Elshaug and colleagues identified chlamydia screening of under-25-year-olds in the general population as a potentially low-value health care practice.1 They cite a systematic review that found that evidence from randomised controlled trials (RCTs) on the impact of chlamydia screening on reducing pelvic inflammatory disease (PID) was limited to high-risk populations, had methodological limitations and had never involved repeated rounds of screening.2 However, a recent RCT of a single round of screening, although underpowered to find a difference in PID incidence, did find that 9.5% of women with untreated chlamydia developed PID, compared with 1.6% of those who were treated (relative risk, 0.17; 95% CI, 0.17–1.01).3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We are all named investigators on a clinical trial of a chlamydia testing intervention in general practice funded by the Department of Health and Ageing and National Health and Medical Research Council. This trial is currently in progress.